Prime Hospital Rewari offers a basic explainer on tirzepatide versus insulin and says to use either only under medical supervision.
Recap by typeshit. Post by @primehospitalrewari on Instagram.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
Exercise guidance aimed at people on GLP-1 medications. Only the title is available, so tap through for the actual recommendations.
Novo reports on November 4. Sydbank keeps its buy rating but expects ongoing pressure from pricing and competition, per Investseekers.
Loading…